For paediatric patients with chronic-phase Ph+ CML, can different bosutinib tablet strengths and hard capsules be combined according to the Zentiva product, Bosutinib 400 mg film-coated tablets?

Yes—the Zentiva product Bosutinib 400 mg film-coated tablets allows combining different bosutinib film-coated tablet strengths and/or hard capsules as appropriate to attain the desired dose for paediatric newly diagnosed or resistant/intolerant chronic-phase Ph+ CML; below 6 years no dose recommendations are possible, and below 1 year safety/efficacy are unestablished.